Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Lucia Y Chen, Michael Amatangelo, Adolfo Aleman, Oliver Van Oekelen, Tania Nevers, Yongliang Sun, William E. Pierceall, Katerina Kappes, Anna Blangiardo, Sundar Jagannath, Cesar Rodriguez, Samir Parekh

Blood (2024) 144 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2024-211651

Published: 2024

Journal Articles

A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

Larysa J Sanchez, Erin Moshier, Alex Lieberman-Cribbin, Joshua Richter, Shambavi Richard, Adriana Rossi, Cesar Rodriguez, Santiago Thibaud, Hearn Jay Cho, Samir Parekh, Sundar Jagannath, Ajai Chari

Blood (2024) 144 (Supplement 1): 7043.

https://doi.org/10.1182/blood-2024-211704

Published: 2024

Journal Articles

Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells

Ivan Odak, Lennart Riemann, Samir Parekh, Joshua Brody

Blood (2024) 144 (Supplement 1): 332.

https://doi.org/10.1182/blood-2024-212011

Published: 2024

Journal Articles

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Blood (2024) 144 (Supplement 1): 357.

https://doi.org/10.1182/blood-2024-204929

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders

Yuefan Huang, Riya Dilip Thakkar, Katerina Kappes, Kristan Steffen, Oliver Venn, Rita Shaknovich, Qinwen Liu, Samir Parekh

Blood (2024) 144 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2024-208105

Published: 2024

Journal Articles

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Adolfo Aleman, Rongbao Zhao, Leah Grossman, Rahul Sanawar, Srinivas Aluri, Mani Mohindru, Rudra Prasad Dutta, Sidorela Reci, Junia Vieira, David Melnekoff, Alessandro Lagana, Shriya Desai, Sundar Jagannath, Amit Verma, Samir Parekh

Blood (2024) 144 (Supplement 1): 589.

https://doi.org/10.1182/blood-2024-201194

Published: 2024

Journal Articles

Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma

Leah Grossman, Adolfo Aleman, Morgan van Kesteren, Sidorela Reci, Charles Gleason, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Jessica Nardulli, Hyun Min Kang, Jacob Mischka, Komal Srivastava, Lubbertus CF Mulder, Sundar Jagannath, Florian Krammer, Viviana Simon, Samir Parekh

Blood (2024) 144 (Supplement 1): 4691.

https://doi.org/10.1182/blood-2024-203556

Published: 2024

Journal Articles

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Zachary M Avigan, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2024-202725

Published: 2024

Journal Articles

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Rudra Prasad Dutta, Heng-Huan Lee, Ravi Prakash Shukla, Violetta V Leshchenko, Fanye Meng, Fangfang Yan, Yang Liu, Husnu Kaniskan, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh

Blood (2024) 144 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2024-210591

Published: 2024

Journal Articles

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Junia Vieira, Alison S Park, Edgar Gonzalez-Kozlova, David Melnekoff, Sherry Bhalla, Chaitanya Acharya, Mark Hamilton, George Mulligan, Immune Atlas Network, Hearn Jay Cho, Li Ding, Sacha Gnjatic, Ioannis S Vlachos, Manoj Bhasin, Sundar Jagannath, Samir Parekh, Alessandro Lagana

Blood (2024) 144 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2024-208677

Published: 2024

Journal Articles

Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma

Adolfo Aleman, Leah Grossman, Ariel Kogan Zajdman, Lucia Y Chen, Sidorela Reci, Sundar Jagannath, Samir Parekh

Blood (2024) 144 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2024-201186

Published: 2024

Journal Articles

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Saoirse Bodnar, Tehilla Brander, Zachary M Avigan, William Genthe, David Melnekoff, Alessandro Lagana, Jane Houldsworth, Shambavi Richard, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Hearn Jay Cho, Kenan Onel, Sundar Jagannath, Manisha Balwani, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2024-212204

Published: 2024

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Candace Westgate, Gilles Salles, Stephannie Shih, Margarita Lopatin, Kathryn N. Kurtzman, Katerina Kappes, Oliver Venn, Samir Parekh, Jeffrey M. Venstrom, Anas Younes, Rita Shaknovich

Blood (2023) 142 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2023-186481

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

NARROW

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma

Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only